Mandatory price controls and tendering processes in the Asia Pacific could impact revenues and market access for ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Sandoz CEO Richard Saynor has reportedly stated that the proposal to introduce a Europe-wide list price for new medicines is ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

What’s on the horizon for pharmacy benefits this year, and how might these shifts reshape the way employers think about cost ...

On April 23, Biocon board approved the raising of funds up to Rs 4,500 crore via the issuance of equity shares, ...

Stocks like Sasken Technologies, SBFC Finance, Mangalore Refinery and Petrochemicals, Bhansali Engineering Polymers, Rossari ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).